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Abstract
Cholangiocarcinoma is a rare malignancy associated with poor prognosis and high mortality. Surgical resection is the only
chance for cure depending on careful patient selection. There are no well-conducted studies regarding the role of adjuvant
chemotherapy. Preliminary data suggest that liver transplantation could offer long-term survival in selected patients when
combined with neoadjuvant chemoradiotherapy. The literature regarding treatment results with specific regimens in the
adjuvant setting is limited and no general recommendation can be given. In patients with locally advanced or metastatic
disease, most studies are small, non-randomized phase II trials, and many studies comprise a mix of bile duct cancers,
gallbladder cancer, and either pancreatic or hepatocellular cancers. In metastatic cancer, phase II studies with several
cytotoxics, including gemcitabine, the platinums, and the fluoropyrimidines, have shown a modest and often short-lasting
activity. No single chemotherapy agent or combination regimen can therefore be recommended as a standard of care at
present. In this review, we give an overview of chemotherapy in the adjuvant, neoadjuvant, and advanced settings.
Introduction
Five-year survival rates are 510% for patients with
gallbladder carcinoma and 1040% for those with
cholangiocarcinoma [1]. The treatment of a patient
with cholangiocarcinoma should be the subject of a
multidisciplinary approach. The lack of randomized
trials in the field renders the decision-making process
difficult. Based on retrospective series of patients
with cholangiocarcinoma, resection can certainly offer
cure depending on the extent of the disease and
quality of the surgery. We review the impact  if any 
of chemotherapy in the adjuvant, neoadjuvant, and
advanced setting.
Adjuvant chemotherapy following surgery with
curative intent
The only treatment that offers a chance for cure in
patients with bile tract cancer is complete surgical
resection. Case series in expert and high volume
centers have demonstrated that extensive surgery is
possible with acceptable morbidity and mortality [2].
However, many patients suffer from recurrent disease,
either locoregional or metastases. Adjuvant chemo-
(radio)therapy has been studied in phase III studies,
but mixing up patients with periampullary and
pancreatic head cancers [3]. There have been several
small studies suggesting some benefit from adjuvant
chemotherapy in certain subgroups, but a consistent
benefit has not been demonstrated for adjuvant.
A recent update from a larger study of adjuvant
chemoradiotherapy did not show a benefit versus
observation [4]. There are no well-conducted studies
regarding the role of adjuvant chemotherapy following
resection of intrahepatic, extrahepatic cholangiocarci-
noma or gallbladder cancers. These studies are difficult
to perform.
In daily clinical practice, patients at our center are
followed clinically and undergo 6-monthly computed
tomography (CT) of the abdomen to detect early
recurrence.
Chemotherapy in patients with advanced biliary
tract cancer
More than 10 years ago, a Scandinavian group
published a randomized trial of chemotherapy
(5-fluorouracil, folinic acid9etoposide) versus best
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supportive care in 93 patients with metastatic biliary
and pancreatic cancer. The trial questioned the
nihilistic attitude adopted by some clinicians [5].
There was an improvement of survival and quality
of life (QOL) in the treated group. However, the
subgroup of patients with bile duct cancer was too
small (37 patients) to yield any significant difference
in overall survival (6 months versus 2.5 months).
There was a significant benefit though for QOL, with
more patients in the treated group having an improved
or high QOL (33% versus 5%; pB0.001).
So far, more than 120 trials on chemotherapy for
advanced biliary tract cancer have been published
since 1985, including nearly 3,000 patients. Most of
these trials have been small, non-randomized phase II
studies, which were pooled in a recent systematic
review [6]. This analysis demonstrated a significant
correlation between response rate, disease control
rate and overall survival, which is also known for
other tumors. Tables I and II summarize the results
of a few studies on single agent chemotherapy [712]
and combination treatment [1318], respectively.
Despite the efforts of some authors, it remains an
impossible task to compare these trials because of
selection bias. Many studies show a worse survival
for patients with gallbladder carcinoma compared to
Table I. Selection of phase II studies of monochemotherapy in advanced biliary tract cancer.
Location n
Response
rate (%)
Progression free
survival (months)
Overall survival
(months)
5-Fluorouracil/folinic acid
Chen et al. 1998 [7] Cholangiocarcinoma 13
33 4 7
Gallbladder 6
Choi et al. 2000 [8] Biliary tract 28 32 NR 6
Gemcitabine
Kubicka et al. 2001 [9] Cholangiocarcinoma 23 30 NR NR
HCC 20 5 NR NR
Gallardo et al. 2001 [10] Gallbladder 26 35 NR 7.5
Park et al. 2005 [11] Cholangiocarcinoma 15
26.1 8.1 13.1
Gallbladder 8
S1 (oral fluoropyrimidine derivative)
Ueno et al. 2004 [12] Gallbladder 16
21.1 3.7 8.3
Cholangiocarcinoma 3
NR: not reported; HCC: hepatocellular carcinoma.
Table II. Phase II studies of combination chemotherapy in advanced biliary tract cancer.
Location n
Response
rates (%)
Progression free
survival (months)
Overall survival
(months)
Gemcitabineoxalipatin
Andre´ et al. 2004 [13] Gallbladder 11 30
Intrahepatic CC 16 21 5.7 15.4
Extrahepatic CC 4 25
Gemcitabinecisplatin
Kim et al. 2006 [14] Gallbladder 10
34.5 3 11
Non-gallbladder CC 19
Gemcitabinecapecitabine
Riechelmann et al. 2007 [15] Gallbladder 27
29 6.2 12.7
Non-gallbladder CC 48
Capecitabineoxaliplatin
Nehls et al. 2008 [16] Gallbladder 27 25 4.7 8.0
Intrahepatic CC 18 0 2.2 5.2
Extrahepatic CC 20 30 11.3 16.6
5FU/folinic acidcisplatin
Taieb et al. 2002 [17] Gallbladder 10
34 6.5 9.5
Cholangiocarcinoma 19
S1cisplatin
Kim et al. 2008 [18] Gallbladder 16
30 4.8 8.7
Non-gallbladder CC 35
CC: cholangiocarcinoma.
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those with extrahepatic cholangiocarcinoma. In one
study with the combination of capecitabine and
oxaliplatin, no responses were noted for intrahepatic
cholangiocarcinoma, while 27% of patients with other
locations had a response [16]. In future phase III
studies, patients should be stratified according to
location of the primary tumor.
There are only three randomized studies in the
setting of advanced biliary tract cancer, and these
are summarized in Table III [1921]. The first study
compared two mitomycin C (MMC) combinations
and suggested a better activity of MMCcapecita-
bine than for MMCgemcitabin [19]. The EORTC
trial [20] showed a higher response rate for the
combination of cisplatin, 5-FU and folinic acid versus
high dose 5-FU, at the cost of more toxicity. The third
study was underpowered to show a difference between
the two arms [21].
Based on the current literature, it is clear that
there are several options that can be proposed for
patients with advanced biliary tract cancer. Patients
with a good performance status can benefit from
combination chemotherapy, which consists of two
of the following drugs: gemcitabine, 5-FU/FA (or
capecitabine) or a platinum analog. These schedules
may yield response rates between 20% and 30% and
offer median survival rates of 812 months. Patients
with gallbladder cancer or intrahepatic cholangiocar-
cinoma do worse compared to those with the extra-
hepatic cancer locations.
Targeted therapy for advanced biliary tract
cancer
Recently, more insights have been gathered on the
biology of bile duct cancer, which can occur anywhere
on the path between the finest ramifications of the
bile duct tree towards the ampulla from Vater. The
carcinogenic process includes the transformation of
normal bile duct cells or possibly stem cells  through
dysplastic lesions  towards cancer. Several abnorm-
alities in tumor suppressor genes (e.g. p16, p27,
p53 . . .) and oncogenes (beta-catenin, ERK, Ras,
c-neu . . .) have been identified. Epidermal growth
factor receptor (EGFR) has been shown to be
activated by bile acids and induces cyclooxygenase-2
expression that may participate in the genesis and
progression of cholangiocarcinoma [22]. This increas-
ing knowledge has resulted in two phase II trials with
Her2-neu or EGFR inhibitors lapatinib or erlotinib,
which have shown little or no activity (0% and 8%
responses, respectively) in advanced biliary system
adenocarcinomas [23,24]. Interestingly, a small study
of cetuximab in 9 patients with tumor resistance to
gemcitabine and oxaliplatin (GEMOX) has shown the
possibility of reversal of resistance to GEMOX [25].
Multimodality treatment
A remarkable success of a neoadjuvant protocol from
the Mayo Clinic has been reported in patients with
unresectable hilar cholangiocarcinoma [26]. With the
use of pretreatment radiotherapy (including external
beam and brachytherapy) and subsequent capecita-
bine prior to liver transplantation, they could achieve
a 5-year actuarial survival of 82%. These results are
clearly better than the current results of surgery for
resectable cholangiocarcinoma. Only prospective and
randomized trials can define the respective contribu-
tion of the different components of the approach.
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